Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
418
¥ million (year-on-year decrease in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFirst quarter of the fiscal year ending March 20272 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥15,128 million-2.7%
Operating profit¥-121 million
Ordinary income¥-114 million
Net income¥-379 million profit attributable to owners of the parent
Results for the three months of the current quarter
Net Sales¥15,128 million
Operating profit−¥121 million
Ordinary income△¥114 million
Profit attributable to owners of parent for the quarter–¥379 million
Full-year earnings forecast
Net Sales
¥66,000 million
Operating profit
¥1,000 million
Ordinary income
¥900 million
Profit attributable to owners of the parent
¥600 million
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
US dollars
¥150
Euro
¥175
Singapore dollars
¥117
Segment results
Japan
Net Sales
¥10,574 million+0.3%
Profit
¥145 million +19.9%on an ordinary income basis
Singapore
Net Sales
¥5,191 million-7.9%
Profit
¥-124 million on an ordinary income basis
China
Net Sales
¥1,181 million+28.0%
Profit
¥111 million on an ordinary income basis
Philippines
Net Sales
¥901 million+7.4%
Profit
¥-160 million on an ordinary income basis
Germany
Net Sales
¥956 million-11.5%
Profit
¥104 million -19.1%on an ordinary income basis
Other
Net Sales
¥1,121 million-24.4%
Profit
¥-54 million on an ordinary income basis
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥15,128 million (YoY -2.7%) |
| Operating profit | ¥-121 million |
| Ordinary income | ¥-114 million |
| Net income | ¥-379 million (profit attributable to owners of the parent) |
| Results for the three months of the current quarter | Net Sales ¥15,128 million / Operating profit −¥121 million / Ordinary income △¥114 million / Profit attributable to owners of parent for the quarter –¥379 million |
| Full-year earnings forecast | Net Sales ¥66,000 million / Operating profit ¥1,000 million / Ordinary income ¥900 million / Profit attributable to owners of the parent ¥600 million |
| Segment results | Japan Net Sales ¥10,574 million (YoY +0.3%) / Profit ¥145 million (on an ordinary income basis) (YoY +19.9%) / Singapore Net Sales ¥5,191 million (YoY -7.9%) / Profit ¥-124 million (on an ordinary income basis) / China Net Sales ¥1,181 million (YoY +28.0%) / Profit ¥111 million (on an ordinary income basis) / Philippines Net Sales ¥901 million (YoY +7.4%) / Profit ¥-160 million (on an ordinary income basis) / Germany Net Sales ¥956 million (YoY -11.5%) / Profit ¥104 million (on an ordinary income basis) (YoY -19.1%) / Other Net Sales ¥1,121 million (YoY -24.4%) / Profit ¥-54 million (on an ordinary income basis) |
| Assumptions Underlying the Business Outlook | US dollars ¥150 / Euro ¥175 / Singapore dollars ¥117 |
Items this document does not state (21)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although sales were strong in the cancer treatment field and for AVF needles for overseas markets, net sales declined due to lower sales of blood bags and other products for overseas markets. On the earnings side, while lower sales of products for overseas markets had an adverse impact, the benefits of cost reductions and a smaller foreign exchange loss contributed to a narrower loss.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.